Kornimate/medical-research-clean huggingface dataset:
treatment of chronic immune thrombocytopenic purpura (itp) with intravenous immunoglobulin igpro10

Conditions: Immune Thrombocytopenic Purpura

Summary: the purpose of this study is to evaluate the efficacy, tolerability and safety of igpro10 in the treatment of patients with chronic immune thrombocytopenic purpura (itp). the main efficacy parameter is the proportion of patients responding to treatment by an increase of platelet count to ≥ 50 x 10\^9/l.


Eligibility criteria:
key inclusion criteria: * diagnosis of chronic itp defined by: failure to find other causes of thrombocytopenia; platelet count ≤ 150 x 10\^9/l over 6 months or response to a previous treatment with subsequent decrease in platelet count even if duration of chronic itp is less than 6 months * platelet counts ≤ 20 x 10\^9/l key exclusion criteria: * planned splenectomy throughout the study period * treatment with ivig or anti-d immunoglobulin within 3 weeks prior to screening * treatment with immunosuppressive or other immunomodulatory drugs within 3 weeks prior to screening * treatment with intravenous steroids within 10 days prior to screening * change of oral steroid treatment within 15 days prior to screening * patients with known or suspected hypersensitivity to immunoglobulins or previous severe side effects to immunoglobulin therapy * abnormal results in the following laboratory parameters: hemoglobin \ 1.5 x upper normal limit; alat \> 2.5 x upper normal limit; asat \> 2.5 x upper normal limit; creatinine \> 1.5 x upper normal limit; urea \> 1.5 x upper normal limit * positive direct coombs test * patients with one of the following concomitant diseases clinical active sle known or suspected hiv infection acute hepatitis clinically active chronic hepatitis lymphoproliferative disease heart failure grade iii or iv according to the new york heart association classification * any other concomitant disease that has influence on the clotting system (i.e. hemophilia)

Keywords: chronic immune thrombocytopenic purpura chronic idiopathic thrombocytopenic purpura werlhofs disease autoimmune thrombocytopenia immunglobulin intravenous chronic itp platelet count thrombocytopenia
safety and feasibility study of robotic assisted transanal total mesorectal excision for rectal cancer

Conditions: Rectal Cancer; Perioperative Complication

Summary: total mesorectal excision has greatly reduced the local recurrence rate of rectal cancer after colorectal surgery. transanal total mesorectal excision(tatme) is potentially a suitable option for patients with middle and low rectal cancer. robotic systems are expected to develop the advantages of tatme to overcome the limitations of laparoscopic surgery. this study aimed to investigate the safety and feasibility of robotic assisted transanal total mesorectal excision in patients with rectal cancer.

tatme is potentially a suitable option for patients with middle or low rectal cancer, especially for males with obesity and a narrow pelvis.the da vinci robotic system (intuitive surgical, sunnyvale, ca, usa) is expected to overcome the limitations of the laparoscopic transanal approach for rectal surgery. da vinci si surgical system or da vinci xi surgical system would be used to performed transanal total mesorectal excision. and the surgery would performed by two-team approach. this study aimed to investigate the safety and feasibility of robotic assisted transanal total mesorectal excision in patients with rectal cancer.

Eligibility criteria:
inclusion criteria: 1. pathological biopsy confirmed adenocarcinoma of the rectum. 2. preoperative assessment of tolerance to surgery without major organ dysfunction. 3. patients must be able to understand and voluntarily sign written informed consent. 4. the surgical method is robotic assisted transanal total mesorectal excision 5. distance of the edge of the tumour within 8 cm exclusion criteria: 1. the patient cannot tolerate the operation. 2. refusal to sign informed consent. 3. patients with distant metastasis of rectal cancer. 4. the surgical method was changed to miles or hartman; 5. unable to complete the follow - up

Keywords: rectal cancer robotic surgery
management of myopia in university students using dual focus soft contact lenses

Conditions: Myopia, Progressive

Summary: the purpose of the study is to quantify the effectiveness of coopervision misight contact lenses in slowing the rate of myopia progression in university students.

misight contact lenses have been shown to be a safe and effective way of managing myopia progression in children aged 8-12 years. however, myopic progression is not limited to children of this age group and misight lenses have also been shown to be effective in older children aged 11-16 years. there is evidence that progression also occurs in university students. the researchers are therefore investigating the effectiveness of this intervention in a group of uk-based university students.

Eligibility criteria:
inclusion criteria: * be a myopic students studying at university * be aged 18-21 years at the start of the study * show evidence of recent myopia progression prior to commencement of stage 2 of the study. * have read the patient information sheet and be happy to sign the consent forms * be willing to adhere to the visit schedule and wearing times described in this protocol * agree to lens wearing times of at least 10 hours per day, 6 days per week * agree to accept either the control or test lens as assigned by the randomisation * have bcva of +0.10 logmar or better in each eye exclusion criteria: * previous myopia control use (optical or pharmacological) * amblyopia * ocular pathology such as keratoconus or recurrent corneal infections * myopic rx \> 10d * astigmatism \>1d * anisometropia \>1.75d * binocular vision anomalies (such as tropia) * medications that affect pupil size or accommodation * a known allergy to fluorescein or tropicamide * biomicroscopic findings that would contraindicate contact lens wear * the investigator considers that it is not in the best interest of the subject to participate in the study.
dopamine agonist for hemispatial neglect and motor deficit post stroke

Conditions: Right Hemisphere Stroke; Hemispatial Neglect; Motor Deficit

Summary: the aim of this study is to assess the effect of the drug rotigotine on the syndrome of hemispatial neglect and motor deficits following strokes affecting the right hemisphere of the brain.

hemispatial neglect and motor deficits remain major problems following right-hemisphere stroke. this study aims to assess the effect of rotigotine on hemispatial neglect, its component cognitive deficits (including spatial working memory and sustained attention) and motor deficits following right-hemisphere stroke.

Eligibility criteria:
inclusion criteria: * confirmed clinical diagnosis of right-hemisphere stroke. * able to give informed consent. * presence of left hemispatial neglect defined by a deficit in finding leftward targets on standard cancellation or visual search tests68-70. (a deficit on the line bisection test alone will not be sufficient for inclusion, as a previous study shows that there is no significant relationship between performance on this test and spatial working memory capacity37). * presence of motor deficits: all patients will have suffered from first-ever clinically defined stroke resulting in weakness of at least wrist and finger extensors, and hand interossei (to \</= 4+ on the medical research council scale), at the time of recruitment. * age over 18 years. * more than 9 days since stroke-onset (note that on our protocol patches do not commence until a minimum of 6 days after the study begins. thus patients will not receive drug / placebo until a minimum of 15 days post-stroke). * able and willing to use patches of drug/placebo and assessments at regular intervals as defined by the protocol. * able to comply with study requirements. * if female and of child-bearing potential, subject has a negative serum pregnancy test within two days of enrollment. exclusion criteria: * pre-existing neurological conditions that would confound cognitive and motor assessments, e.g. dementia, parkinson's disease, multiple sclerosis. * presence of acute concomitant illness, e.g. infection, unstable angina, myocardial infarction or heart, respiratory, renal or liver failure which, based on clinical judgment, would be considered to confound interpretation of results. * systolic blood pressure less than 120 mmhg and / or diastolic less than 70 mmhg. * exposure to any other investigational drug within 30 days of enrollment in the study. * history (obtained from patient and medical records) of clinically significant drug or alcohol abuse within 6 months prior to enrollment into the study. * pregnancy (because the effects of rotigotine on the fetus and mother in pregnancy are not known). if female and of child-bearing potential, a serum pregnancy test will be performed within two days of enrollment. * mothers who are breast feeding (because the effects of rotigotine on the newborn have not been established)

Keywords: stroke hemispatial neglect unilateral neglect spatial neglect motor weakness
antifungal agents and infrared thermotherapy alone or in combination in the treatment of sporotrichosis

Conditions: Sporotrichosis

Summary: sporotrichosis is a chronic granulomatous mycosis caused by sporothrix complex. the course of sporotrichosis is always prolonged and even life-threatening, the treatment of this disease in an important scientific problem to be solved. the investigators previously found the predominance of subtype m2 macrophage which play an anti-inflammatory role in the lesions of sporotrichosis, the predominance of m2 macrophage may be responsible for the persistence of sporotrichosis; the investigators also found that local hyperthermia is effective in the treatment of sporotrichosis and hyperthermia treatment can activate the crac calcium channel in macrophages which triggers pro-inflammatory type m1 polarization and subsequent killing of sporothrix, however, the mechanism still calls for further investigation. the investigators hypothesize that hyperthermia leads to the activation of crac channels resulting in profound ca2+ influx and ca2+ upregulates nlrp3 inflammasome expression through inducing nrf2 activation, then nlrp3 overexpression triggers m1 polarization and subsequent killing of sporothrix. furthermore, the activation of nrf2 upregulates stim1 expression which forms a positive feedback for m1 type polarization of macrophages and further subsequent killing of sporothrix. the purpose of this project is to identify the hypothesis that hyperthermia could treat sporotrichosis by promoting pro-inflammatory type m1 polarization in macrophages, the mechanism by which hyperthermia could treat sporotrichosis is local hyperthermia could led to stim1/crac calcium channel activation mediated calcium ions/nrf2/nlrp3 induced m1 macrophages polarization and subsequent killing of sporothrix. the hypothesis will be identified at the cellular level, at the animal model level and at the clinical specimens level. the investigators believe that the project will guide the application of hyperthermia in the treatment of sporotrichosis and provide a new basis of theory and practice after the investigators achieving these goals.


Eligibility criteria:
inclusion criteria: * the results of pathology and fungal culture were all patients with sporotrichosis. * informed consent to the purpose and content of the study, and follow-up as required * the physical condition and self-condition can cooperate with the treatment. exclusion criteria: * subjects who are unable to maintain a relatively stable posture during treatment. * those who are sensitive or allergic to this experimental drug. * systemic antifungal or ki therapy within 12 months * local antifungal therapy within 1 month. * previous history of immunodeficiency virus (hiv) infection, or positive hiv antibody in screening period.

Keywords: sporotrichosis local hyperthermia
cardiac resynchronization therapy defibrillator based impedance monitoring study

Conditions: Heart Failure

Summary: the intent of this feasibility study is to collect and analyze intra-thoracic impedance measurements from a crt-d device in a heart failure population.

this is a multi-center feasibility study intended to collect information on changes in intra-thoracic impedance measurements from crt-d devices. in order to obtain an intra-thoracic impedance measurement, the device delivers a subthreshold impulse that measures the resistance between two electrodes. at the programmed interval, measurements will be obtained between six different lead configurations.

Eligibility criteria:
inclusion criteria: eligible patients will meet all of the following: 1. have an approved indication per american college of cardiology/american heart association/heart rhythm society guidelines for implantation of a cardiac resynchronization therapy defibrillator (crt-d) or have a previously implanted st. jude medical (sjm) crt-d system capable of enabling the diagnostic impedance monitoring feature with implant occurring within the last 14 days 2. have had at least one hospitalization, emergency department visit, or clinic visit within the past 12 months for treatment of decompensated heart failure requiring intravenous diuretics, intravenous inotropes, natrecor (nesiritide) therapy, or an increase in an oral diuretic of ≥100% over a 24 hour period 3. have the ability to maintain a patient diary for recording daily weights, symptoms related to heart failure, changes in diuretic therapy, and any unscheduled clinic or hospital visits 4. have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluation exclusion criteria: patients will be excluded if they meet any of the following: 1. be less than 18 years of age 2. have had a recent myocardial infarction, unstable angina or cardiac revascularization within 40 days of enrollment 3. have had a recent cerebrovascular accident or transient ischemic attack within three months of enrollment 4. have a contraindication for an emergency thoracotomy 5. have an indication that requires programming device in atrial pacing mode 6. have permanent (chronic) atrial fibrillation 7. have a capped or inactive right atrial or right ventricular pacing/defibrillator lead 8. have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate or short term contact with heparin 9. be pregnant or planning a pregnancy in the next 6-months 10. be currently participating in a clinical investigation that includes an active treatment arm 11. have a life expectancy of less than six months due to any condition

Keywords: cardiac resynchronization therapy transthoracic impedance
depression and transcranial direct current stimulation (tdcs)

Conditions: Depression

Summary: transcranial direct current stimulation (tdcs)is a non invasive technique which uses a very weak current to change excitability in targeted regions of the brain. early studies suggest that it has antidepressant properties. this study will test the safety and efficacy of tdcs as a treatment for depression.

transcranial direct current stimulation (tdcs) applies a weak direct current across the scalp that can produce sub-threshold changes in the excitability of targeted cortical regions, in a polarity-specific manner. this technique has been used in humans to alter motor and visual cortex excitability, during stimulation, and for a period after the stimulation has ceased. it has therefore been suggested as a possible treatment for depression (lippold \& redfearn, 1964; nitsche, 2002). studies have been launched recently to examine the effect of tdcs in depressed subjects and a sham-controlled pilot study (in usa, in press) has reported promising antidepressant effects with tdcs. we wish to examine this in an investigation of 20 subjects, and hypothesise that tdcs will have an antidepressant effect and produce no neuropsychological impairment. subjects will receive anodal dc stimulation or sham stimulation over the left prefrontal cortex in a double-blind, placebo-controlled design over 5 days, and then have daily stimulation up to a maximum of 10 active sessions in total. outcomes will be formally evaluated by depression rating scales and neuropsychological tests.

Eligibility criteria:
inclusion criteria: * dsm-iv major depressive episode of less than or equal to 3 years * montgomery-asberg depression rating scale score of 25 or more * aged 18-65 * may or may not be taking antidepressant medication exclusion criteria: * not able to give written informed consent * failure to respond to ect in current or past episodes of depression * on antipsychotic, anticonvulsant or benzodiazepine medication which cannot be withdrawn. * significant other axis i psychiatric disorder e.g schizophrenia, bipolar * in imminent physical or psychological danger and needs a rapid clinical response due to inanition, psychosis or high suicidality * drug or alcohol dependence or abuse currently or in the last 12 months * history of neurological illness e.g epilepsy; neurosurgical procedure * metal in the cranium, pacemaker, cochlear implant, medication or other electronic device in the body * woman of child-bearing age in whom pregnancy cannot be ruled out by b hcg

Keywords: depression transcranial direct current stimulation
non-inferiority study comparing 3 weekly injections of supartz® vs 3 weekly injections of euflexxa® for knee oa

Conditions: Osteoarthritis

Summary: the purpose of this study is to demonstrate non-inferiority of three weekly intra-articular injections of supartz to three weekly intra-articular injections of euflexxa for the relief of knee oa.

the purpose of this study is to demonstrate non-inferiority of three weekly intra-articular injections of supartz to three weekly intra-articular injections of euflexxa for the relief of knee joint pain in subjects with osteoarthritis (oa) of the knee as measured by the vas (0-100 mm) western ontario and mcmaster universities osteoarthritis index (womac) pain subscale score change from baseline (cfb) over weeks 3, 6, 12. safety will be accessed by recording adverse events, concomitant medications, physical examinations, and vital signs.

Eligibility criteria:
inclusion criteria: * clinical evidence of symptomatic osteoarthritis of the study knee as classified according to altman criteria. * symptoms in study knee for at least one year prior to the screening visit * verified oa of the study knee of grade 2 or 3 according to a modification of the grading system of kellgren-lawrence (k-l) radiographic severity. * willingness to discontinue nsaids (systemic and topical) and non-acetaminophen analgesic use seven days or five half-lives prior to the first injection and throughout the study. exclusion criteria: * inability to perform a 50 foot walk test. * subjects with rheumatoid arthritis, joint infection, other inflammatory and metabolic arthritis, lupus or dermatologic disorder or skin conditions in close proximity to study knee that would preclude safe intra-articular injections. * prior hyaluronic acid injections into the study knee within six months of the screening visit. * intra-articular or intra-muscular steroid injections within three months of the screening visit or during study participation. oral corticosteroids within four weeks of the screening visit or during study participation. * history of surgical treatment to the study knee or arthroscopic intervention within three months prior to the screening visit. * clinically apparent tense effusion of the study knee on examination determined by either a positive bulge sign or positive ballottement of the patella (patellar tap). * subjects with clinically diagnosed symptomatic oa of the hip.

Keywords: osteoarthritis knee pain supartz euflexxa ha hyaluronic acid
effect of covid-19 pandemic on pediatric cancer care

Conditions: Covid19

Summary: observational cohort study to assess the effects of covid19 on pediatric cancer care in egypt and the arab world through a survey applied to pediatric oncologists who will be interviewed either directly or through the internet to assess the effect of covid 19 on pediatric cancer care

corona viruses are single stranded enveloped rna viruses with helical capsids. they infect wide variety of hosts including humans and animals. coronavirus disease 2019 (covid-19) was first described in december 2019 in wuhan, the capital of china's hubei province. a novel corona virus named severe acute respiratory syndrome coronavirus 2 (sars-cov-2) was identified as the causative organism. on 30 jan 2020, who declared covid-19 as a public health emergency of international concern (pheic). subsequently on 11 march 2020, who declared covid-19 as a pandemic. on april 30, 2020; 3,239,220 confirmed cases were diagnosed across the globe with 228,860 deaths. the united states has the highest number of cases followed by spain and italy. the first confirmed case of covid-19 in egypt was reported on 14 february 2020. as of april 30, 2020, there have been 5,537 confirmed cases, 1381 recovered and 392 deaths the overall global incidence of cancers in children aged 0-14 years is 140·6 per million, whereas, it's 130.9 per million in egypt. although cancer is a rare disease among children and adolescent, it's one of the leading causes of death. the prognosis of childhood cancer has significantly improved over the past decades with 5-year survival rates improved from 58% in the mid-1970 to around 83% in 2008-2014. little is known about the effects of covid-19 on children with cancer. children with cancer face numerous challenges during covid-19 pandemic. children with cancer are immunocompromised because of cancer or anti-cancer therapy. they have to be hospitalized to receive their anti-cancer therapy. the major problem we-as pediatric oncologist- face nowadays is how to organize pediatric cancer care in the covid-19 era.

Eligibility criteria:
inclusion criteria: * pediatric oncologists working in cancer centers in egypt and the arab world during covid 19 pandemic exclusion criteria: * pediatric oncologists not caring for patients during covid 19 pandemic

Keywords: pediatric oncology, covid 19